Search research articles
Contact Us
Filters
Showing results (31-40 of 91) with videos related to
Page
of 10
Sort By:
Cancer Biotherapy & Radiopharmaceuticals
|
August 24, 2005
Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein
Andres Forero-Torres, Sui Shen, Hazel Breitz, et al.
Blood
|
October 18, 2017
Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL
Jonathan W Friedberg, Andres Forero-Torres, Rodolfo E Bordoni, et al.
British Journal of Haematology
|
September 6, 2018
An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma
David J Andorsky, Kathryn S Kolibaba, Sarit Assouline, et al.
Breast Cancer Research and Treatment
|
February 3, 2023
A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer
Christos Vaklavas, Erica M Stringer-Reasor, Ahmed M Elkhanany, et al.
Blood
|
September 18, 2015
Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older
Andres Forero-Torres, Beata Holkova, Jerome Goldschmidt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 20, 2014
Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study
Michelle A Fanale, Steven M Horwitz, Andres Forero-Torres, et al.
Leukemia & Lymphoma
|
December 24, 2013
Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy
Ajay K Gopal, Nancy L Bartlett, Andres Forero-Torres, et al.
Journal of Hematology & Oncology
|
March 20, 2014
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
Nancy L Bartlett, Robert Chen, Michelle A Fanale, et al.
Journal of Hematology & Oncology
|
June 13, 2014
A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors
Sven de Vos, Andres Forero-Torres, Stephen M Ansell, et al.
Molecular Cancer Therapeutics
|
February 21, 2014
Effect of niclosamide on basal-like breast cancers
Angelina I Londoño-Joshi, Rebecca C Arend, Laura Aristizabal, et al.
Page
of 10
Search research articles
Search
Showing results (31-40 of 91) with videos related to
Sort By:
Page
of 10
Cancer Biotherapy & Radiopharmaceuticals
|
August 24, 2005
Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein
Andres Forero-Torres, Sui Shen, Hazel Breitz, et al.
Blood
|
October 18, 2017
Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL
Jonathan W Friedberg, Andres Forero-Torres, Rodolfo E Bordoni, et al.
British Journal of Haematology
|
September 6, 2018
An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma
David J Andorsky, Kathryn S Kolibaba, Sarit Assouline, et al.
Breast Cancer Research and Treatment
|
February 3, 2023
A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer
Christos Vaklavas, Erica M Stringer-Reasor, Ahmed M Elkhanany, et al.
Blood
|
September 18, 2015
Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older
Andres Forero-Torres, Beata Holkova, Jerome Goldschmidt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 20, 2014
Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study
Michelle A Fanale, Steven M Horwitz, Andres Forero-Torres, et al.
Leukemia & Lymphoma
|
December 24, 2013
Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy
Ajay K Gopal, Nancy L Bartlett, Andres Forero-Torres, et al.
Journal of Hematology & Oncology
|
March 20, 2014
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
Nancy L Bartlett, Robert Chen, Michelle A Fanale, et al.
Journal of Hematology & Oncology
|
June 13, 2014
A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors
Sven de Vos, Andres Forero-Torres, Stephen M Ansell, et al.
Molecular Cancer Therapeutics
|
February 21, 2014
Effect of niclosamide on basal-like breast cancers
Angelina I Londoño-Joshi, Rebecca C Arend, Laura Aristizabal, et al.
Page
of 10